Strides Pharma Science Limited
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products f… Read more
Strides Pharma Science Limited (STAR) - Total Assets
Latest total assets as of September 2025: ₹65.21 Billion INR
Based on the latest financial reports, Strides Pharma Science Limited (STAR) holds total assets worth ₹65.21 Billion INR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Strides Pharma Science Limited - Total Assets Trend (2005–2025)
This chart illustrates how Strides Pharma Science Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Strides Pharma Science Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Strides Pharma Science Limited's total assets of ₹65.21 Billion consist of 51.2% current assets and 48.8% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹0.00 | 2.3% |
| Accounts Receivable | ₹12.03 Billion | 19.9% |
| Inventory | ₹12.78 Billion | 21.1% |
| Property, Plant & Equipment | ₹0.00 | 0.0% |
| Intangible Assets | ₹5.68 Billion | 9.4% |
| Goodwill | ₹5.47 Billion | 9.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how Strides Pharma Science Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Strides Pharma Science Limited's current assets represent 51.2% of total assets in 2025, an increase from 47.1% in 2005.
- Cash Position: Cash and equivalents constituted 2.3% of total assets in 2025, down from 4.4% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 18.0% of total assets, an increase from 4.0% in 2005.
- Asset Diversification: The largest asset category is inventory at 21.1% of total assets.
Strides Pharma Science Limited Competitors by Total Assets
Key competitors of Strides Pharma Science Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Strides Pharma Science Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Strides Pharma Science Limited generates 0.76x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Strides Pharma Science Limited generates $ 59.41 in net profit.
Strides Pharma Science Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.15 | 1.04 | 0.93 |
| Quick Ratio | 0.64 | 0.64 | 0.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₹4.23 Billion | ₹ 1.30 Billion | ₹ -1.89 Billion |
Strides Pharma Science Limited - Advanced Valuation Insights
This section examines the relationship between Strides Pharma Science Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.90 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 3.6% |
| Total Assets | ₹60.49 Billion |
| Market Capitalization | $572.99 Million USD |
Valuation Analysis
Below Book Valuation: The market values Strides Pharma Science Limited's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Strides Pharma Science Limited's assets grew by 3.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Strides Pharma Science Limited (2005–2025)
The table below shows the annual total assets of Strides Pharma Science Limited from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | ₹60.49 Billion | +3.58% |
| 2024-03-31 | ₹58.40 Billion | -12.03% |
| 2023-03-31 | ₹66.38 Billion | -4.84% |
| 2022-03-31 | ₹69.76 Billion | -0.56% |
| 2021-03-31 | ₹70.15 Billion | +14.03% |
| 2020-03-31 | ₹61.52 Billion | -23.16% |
| 2019-03-31 | ₹80.06 Billion | +22.34% |
| 2018-03-31 | ₹65.44 Billion | -19.38% |
| 2017-03-31 | ₹81.17 Billion | +5.98% |
| 2016-03-31 | ₹76.59 Billion | +208.08% |
| 2015-03-31 | ₹24.86 Billion | +18.44% |
| 2014-03-31 | ₹20.99 Billion | -56.25% |
| 2013-03-31 | ₹47.98 Billion | -12.20% |
| 2012-03-31 | ₹54.64 Billion | +21.61% |
| 2011-03-31 | ₹44.93 Billion | +39.12% |
| 2010-03-31 | ₹32.30 Billion | +38.77% |
| 2009-03-31 | ₹23.27 Billion | +14.46% |
| 2008-03-31 | ₹20.33 Billion | +65.73% |
| 2007-03-31 | ₹12.27 Billion | +31.10% |
| 2006-03-31 | ₹9.36 Billion | +71.20% |
| 2005-03-31 | ₹5.47 Billion | -- |